WebThe impact of innovation. Anti-amyloid therapies to treat Alzheimer’s Disease. Car-T therapies. Combination therapies for lung cancer. Anti-viral therapies for Hepatitis B and HIV. Gene therapies for rare diseases. mRNA vaccines for brain cancer. Remyelinating therapies for e.g. Multiple sclerosis. NASH treatments. WebMay 12, 2024 · (EMA, national competent bodies, HTA bodies)5. A parallel process which aligns the assessment, authorisation and reimbursement decisions of biomarkers and therapies in order to facilitate a simultaneous and consistent assessment of the cost-effectiveness of the biomarker-therapy combinations leading to aligned reimbursement …
Contact us - EFPIA
WebCombination therapies for lung cancer. Anti-viral therapies for Hepatitis B and HIV. Gene therapies for rare diseases. mRNA vaccines for brain cancer. ... EFPIA Code of Practice … WebJan 27, 2024 · A new wave of potentially curative treatments called Advanced Therapy Medicinal Products (ATMPs) has the potential to transform the lives of patients and revolutionise the way we think, manage and resource healthcare. Speaking about today’s publication of a new report on ATMPs, EFPIA Director General, Nathalie Moll said; … chloe hargreaves facebook
EFPIA Homepage
WebMay 25, 2024 · Our analysis of the root causes of these issues shows they are multi-factorial; including late start of market access assessment, duplicative evidence requirements, national pricing and reimbursement policies as well as company decisions driven by a combination of these factors. WebFeb 18, 2024 · Combination therapies for lung cancer. Anti-viral therapies for Hepatitis B and HIV. Gene therapies for rare diseases. ... With this is mind, EFPIA took the step of writing to the European Commission highlighting these concerns, and recommended the following three actions be taken: 1. The requirements described in Article 117 that amend ... WebJun 17, 2024 · Combination therapies for lung cancer. Anti-viral therapies for Hepatitis B and HIV. Gene therapies for rare diseases. ... EFPIA has published a reflection paper on how a platform device approach for a new iDDC product could be developed to allow for a platform NBOp that could be reused whenever the new product lies within the platform ... chloe harlow